Use access key #2 to skip to page content.
$2.32 -0.09 (-3.73%)
7/8/2008 4:01 PM

Javelin Pharmaceuticals, Inc. (JAV)

CAPS Rating:
***

The Company is engaged in the research, development and commercialization of innovative treatments for the relief of moderate to severe pain.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating JAV

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

141 Outperforms
13 Underperforms
 

All-Stars

28 Outperforms
6 Underperforms
 

Wall Street

7 Outperforms
0 Underperforms
 

Players bullish on JAV are also bullish on:

Players bearish on JAV are also bearish on:

Ticker Tags

Micro Cap (4824), Drug Manufacturers - Major (27)
Suggest a tag

Javelin Pharmaceuticals, Inc. At A Glance

Current Price: $2.32
Last Trade Time: 7/8/2008 4:01 PM
Open: $2.41
Previous Close: $2.41
Daily Range: $2.15 - $2.41
52-Week Range: $2.14 - $6.75
Volume: 614,991
Market Cap: $145.85M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

JAV VS S&P 500 (SPY)

JAV 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for JAV

More Headlines...

Top Bull Pitch

Recs

1

Javelin Pharmaceuticals, Inc. (JAV)

Avatar ESTES27112 (< 20) Submitted: 5/16/08 5:01 PM

This stock has been bludgeoned, but has now found and bottom and with 3 drugs in phase 3, this company could see profits within 2 years.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

4

Javelin Pharmaceuticals, Inc. (JAV)

Avatar cut2qr (< 20) Submitted: 3/29/07 1:58 AM

Three drugs for post operative pain relief in phase 3 trials due to report next 3mo with one Wall Street pro saying a "transforming event" is around the corner. Sound's good BUT- 1st candidate is an injectable NSAID (Dyloject) that has been availble orally for 20 yrs, will compete with Toradol the p...More

Replies: 1 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 31 :   1 2 3 4 5 Next »

Recs

0

 (JAV)

Avatar biovestor (36.68) Submitted: 6/30/08 10:03 AM : Outperform Start Price: $2.50 JAV Score: -7.00

A micro-cap specialty pharma focused on pain and unique drug delivery technology, JAV languishes near its lows despite EU approval/launch of Dyloject, two more drugs in pipeline, and work on US approval for Dyloject serving as future catalysts.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (JAV)

Avatar JohnnyiPhone (23.80) Submitted: 6/11/08 11:25 AM : Outperform Start Price: $2.92 JAV Score: -15.07

Penny stock ready!

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (JAV)

Avatar ESTES27112 (< 20) Submitted: 5/16/08 5:01 PM : Outperform Start Price: $3.20 JAV Score: -16.57

This stock has been bludgeoned, but has now found and bottom and with 3 drugs in phase 3, this company could see profits within 2 years.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (JAV)

Avatar bluedome (< 20) Submitted: 5/14/08 9:06 PM : Outperform Start Price: $3.29 JAV Score: -19.58

Technical, going with the bounce and


continuation of today's trend

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (JAV)

Avatar Lennyg02 (< 20) Submitted: 5/10/08 3:28 PM : Outperform Start Price: $2.76 JAV Score: -7.29

Several pain medications in the works (and pain will not go away). One drug has been approved in Europe and is in Phase III in the US. Their intranasal morphine product seems interesting (also in Phase III).

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 31 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLadenburg 75.36 05/14/08 05/14/08 Outperform NS $3.24-28.40%-10.44%-17.96
TrackCanaccord 89.18 01/31/08 01/31/08 Outperform NS $3.67-36.78%-6.26%-30.53
TrackFortisBank 98.33 07/23/07 07/23/07 Outperform NS $5.23-55.64%-17.53%-38.11
TrackJPMorgan 95.01 05/29/07 05/29/07 Outperform NS $7.15-67.55%-16.28%-51.27
TrackPacificGrow 56.32 05/22/07 05/22/07 Outperform NS $6.65-65.11%-16.62%-48.49
TrackPZK < 20 03/15/07 03/15/07 Outperform NS $7.15-67.55%-9.03%-58.53
TrackRodmanRen < 20 01/31/07 01/31/07 Outperform NS $5.05-54.06%-10.82%-43.24

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners